U.S. Markets closed

A Look at Alexion Pharmaceuticals’ Operational Performance

Kenneth Smith
A Look at Alexion Pharmaceuticals’ Operational Performance

For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.